Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy …
SE Frey, A Wald, S Edupuganti, LA Jackson… - Vaccine, 2015 - Elsevier
SE Frey, A Wald, S Edupuganti, LA Jackson, JT Stapleton, H El Sahly, SS El-Kamary…
Vaccine, 2015•ElsevierAbstract Background Modified vaccinia Ankara (MVA) is being developed as a safer
smallpox vaccine and is being placed in the US Strategic National Stockpile (SNS) as a
liquid formulation for subcutaneous (SC) administration at a dose of 1× 10 8 TCID 50 in a
volume of 0.5 mL. This study compared the safety and immunogenicity of the standard
formulation, dose and route with both a more stable, lyophilized formulation and with an
antigen-sparing intradermal (ID) route of administration. Methods 524 subjects were …
smallpox vaccine and is being placed in the US Strategic National Stockpile (SNS) as a
liquid formulation for subcutaneous (SC) administration at a dose of 1× 10 8 TCID 50 in a
volume of 0.5 mL. This study compared the safety and immunogenicity of the standard
formulation, dose and route with both a more stable, lyophilized formulation and with an
antigen-sparing intradermal (ID) route of administration. Methods 524 subjects were …
Background
Modified vaccinia Ankara (MVA) is being developed as a safer smallpox vaccine and is being placed in the US Strategic National Stockpile (SNS) as a liquid formulation for subcutaneous (SC) administration at a dose of 1 × 108 TCID50 in a volume of 0.5 mL. This study compared the safety and immunogenicity of the standard formulation, dose and route with both a more stable, lyophilized formulation and with an antigen-sparing intradermal (ID) route of administration.
Methods
524 subjects were randomized to receive either a full dose of Lyophilized-SC, a full dose of Liquid-SC or 20% (2 × 107 TCID50 in 0.1 mL) of a full dose Liquid-ID MVA on Days 0 and 28. Safety and immunogenicity were followed through 180 days post second vaccination.
Results
Among the 3 groups, the proportion of subjects with moderate/severe functional local reactions was significantly different (P = 0.0013) between the Lyophilized-SC group (30.3%), the Liquid-SC group (13.8%) and Liquid-ID group (22.0%) only after first vaccination; and for moderate/severe measured erythema and/or induration after any vaccination (P = 0.0001) between the Lyophilized-SC group (58.2%), the Liquid-SC group (58.1%) and the Liquid-ID group (94.8%) and the reactions lasted longer in the Liquid-ID group. In the ID Group, 36.1% of subjects had mild injection site skin discoloration lasting ≥6 months.
After second vaccination Day (42–208), geometric mean of peak neutralization titers were 87.8, 49.5 and 59.5 for the Lyophilized-SC, Liquid-SC and Liquid-ID groups, respectively, and the maximum number of responders based on peak titer in each group was 142/145 (97.9%), 142/149 (95.3%) and 138/146 (94.5%), respectively. At 180 days after the second vaccination, geometric mean neutralization titers declined to 11.7, 10.2 and 10.4 with only 54.3%, 39.2% and 35.2% of subjects remaining seropositive for the Lyophilized-SC, Liquid-SC and Liquid-ID groups, respectively. Both the Lyophilized-SC and Liquid-ID groups were considered non-inferior (primary objective) to the Liquid-SC group.
Conclusions
Transitioning to a lyophilized formulation, which has a longer shelf life, will not negatively impact immunogenicity. In a situation where insufficient vaccine is available, ID vaccination could be used, increasing the number of available doses of vaccine in the SNS 5-fold (i.e., from 20 million to 100 million doses).
Elsevier
